BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BSGCT - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://bsgct.org
X-WR-CALDESC:Events for BSGCT
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260729T183000
DTEND;TZID=UTC:20260729T193000
DTSTAMP:20260720T105616Z
CREATED:20260706T140038Z
LAST-MODIFIED:20260720T105616Z
UID:10000011-1785349800-1785353400@bsgct.org
SUMMARY:BSGCT PPE Talk - How to develop a stem cell therapy
DESCRIPTION:Virtual Only \nREGISTRATION IS FREE \nBSGCT Invites you to our next Public and Patient Engagement (PPE) talk. \nIn this talk\, I will cover the pathway scientists follow to take a stem cell therapy from the lab into the hospital. I will focus on our efforts to develop a stem cell therapy for Hirschsprung disease: a congenital disease in which affected children are born missing a nervous system in a variable amount of the distal bowel. Our group is developing a cell therapy to replace these nerves and\, hopefully\, restore bowel function. \nSpeaker  \nDr Benjamin Jevans \nI am dedicated to understanding the processes involved in nerve damage and developing cell-based therapies to repair it. My work has covered spinal cord injury and Parkinson’s disease\, and over the past five years I have focused on Hirschsprung disease\, a congenital condition where children are born missing nerves in the distal bowel. I strongly believe that real progress in treating such conditions depends on bridging the gap between research and the lived experiences of patients and their families. \nThe joining link will be sent to you following registration. \n\n\n\n\nBSGCT PPE Talk – How To Develop A Stem Cell Therapy\n\n\n\n\n\n\n\n\nYour details\n\n\n\n	Title\n		\n	\n	\n	\n	\n\n\n	Name\n		*\n	\n	\n	First\n	\n\n\n	Last Name\n		*\n	\n	\n	Last\n	\n\n\n	Email\n		*\n	\n	\n	\n	\n\n\n	Organisation\n		*\n	\n	\n	\n	\n\n\n	Position / role\n		*\n	\n	\n	\n	\n\n\n	BSGCT Membership Status\n		*\n	\n						\n					 Member\n					\n					 Non-member\n\n	\n	\n\n\n\n	\n\nSubmit\n\n\n\n		\n			\n			\n			\n				If you are human\, leave this field blank.
URL:https://bsgct.org/event/bsgct-ppe-talk-how-to-develop-a-stem-cell-therapy/
CATEGORIES:Online Seminars,Patient and Public Engagement
ATTACH;FMTTYPE=image/png:https://bsgct.org/wp-content/uploads/2026/07/PPE_Twitter-July-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260326T183000
DTEND;TZID=UTC:20260326T191500
DTSTAMP:20260224T090720Z
CREATED:20260223T180857Z
LAST-MODIFIED:20260224T090720Z
UID:10000009-1774549800-1774552500@bsgct.org
SUMMARY:Strategies for AAV capsid engineering
DESCRIPTION:AAV is a promising delivery vehicle for gene therapies with potential to be engineered for improved targeting\, higher potency and lower immunogenicity. However\, challenges also remain to improve their manufacturing and stability to achieve lower costs and ease of formulation and delivery.  Protein engineering provides a viable route to creating platform vectors ready-made for low cost manufacture and high dose formulation. Several protein engineering strategies will be presented for achieving this goal including guidance by bioinformatics\, physical structure calculations\, molecular dynamics simulations\, machine learning\, and generative-AI. New vector designs achieve improved stability\, transduction efficiency\, manufacturing production yield. \nSPEAKER \nProf Paul Dalby is Co-Director of the EPSRC Future Targeted Healthcare Manufacturing Hub\, and Deputy Head of the Department of Biochemical Engineering at UCL.  Paul’s research focuses on technologies to improve the design and formulation of therapeutic proteins and gene therapy vectors\, to improve their manufacture\, stability\, delivery and function.  He has pioneered smart directed evolution approaches that accelerate evolution in the lab. Recent work has used molecular dynamics simulations and computational protein design tools to guide stability and function modifying mutations into proteins and viral vectors. \nThe joining link will be sent to you upon registration. \n\n\n\n\nBSGCT PPE Talk –  Strategies for AAV capsid engineering\n\n\n\n\n\n\n\n\nYour details\n\n\n\n	Title\n		\n	\n	\n	\n	\n\n\n	Name\n		*\n	\n	\n	First\n	\n\n\n	Last Name\n		*\n	\n	\n	Last\n	\n\n\n	Email\n		*\n	\n	\n	\n	\n\n\n	Organisation\n		*\n	\n	\n	\n	\n\n\n	Position / role\n		*\n	\n	\n	\n	\n\n\n	BSGCT Membership Status\n		*\n	\n						\n					 Member\n					\n					 Non-member\n\n	\n	\n\n\n\n	\n\nSubmit\n\n\n\n		\n			\n			\n			\n				If you are human\, leave this field blank.			\n			\n		\n		\n\n\n\n\n\n\n 
URL:https://bsgct.org/event/strategies-for-aav-capsid-engineering/
CATEGORIES:Online Seminars,Patient and Public Engagement,Seminars
ATTACH;FMTTYPE=image/jpeg:https://bsgct.org/wp-content/uploads/2026/02/BSGCT-PostcardsYT-Thumbnails-SF.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260313T100000
DTEND;TZID=UTC:20260313T160000
DTSTAMP:20260216T110740Z
CREATED:20260119T103839Z
LAST-MODIFIED:20260216T110740Z
UID:10000008-1773396000-1773417600@bsgct.org
SUMMARY:School & Public Engagement Day
DESCRIPTION:School students (Years 11-13)\, patients and the public are invited to join us for this FREE interactive event which introduces and explores gene and cell therapy. \nThis is a fantastic opportunity to: \n\nMeet leading scientists\nDiscover cutting-edge research\nHear from patients and those affected by relevant diseases\nExplore career options\nDiscuss the ethical implications and the impact that gene and cell therapy has on society.\n\nPED 2026 Programme \n  \nSponsored by: \n \nSpaces are limited! To reserve your tickets please contact us at info@bsgct.org \n 
URL:https://bsgct.org/event/school-public-engagement-day/
CATEGORIES:Patient and Public Engagement
ATTACH;FMTTYPE=image/png:https://bsgct.org/wp-content/uploads/2026/01/ped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20251210T183000
DTEND;TZID=UTC:20251210T193000
DTSTAMP:20251205T111151Z
CREATED:20251118T182237Z
LAST-MODIFIED:20251205T111151Z
UID:10000007-1765391400-1765395000@bsgct.org
SUMMARY:BSGCT PPE Talk - Going Viral: How To Tame And Train A Virus Into A Cancer Fighting Therapy
DESCRIPTION:Virtual Only. \nREGISTRATION IS FREE – Sign up here to receive the joining link. \nBSGCT Invites you to our next Public and Patient Engagement (PPE) talk. \nJoin Dr Charley Lovatt-Travers is a research associate working with Professor Alan Parker in the Viral ImmunoTherapies and Advanced therapeutics Laboratory (VITAL) at the Division of Cancer and Genetics\, Cardiff University School of Medicine. \nHer current research\, funded by Pancreatic Cancer Research Fund\, focuses on “smart” viruses which are engineered to only infect and kill cancer cells. Her research aims to generate “smarter” viruses which can be used to deliver anti-cancer medicines\, which activate the immune system\, directly to the tumour. Charley’s previous research within the VITAL lab explored the virus-host cell interactions responsible for the very rare cases of blood clots following vaccination with adenovirus-based COVID-19 vaccines. \nPrior to becoming a virus tinkerer\, Charley undertook her PhD exploring new immunotherapy targets for the treatment of lung cancer at the European Cancer Stem Cell Research Institute in Cardiff University. When she is not training viruses\, Charley can be found at home doing crafts and hanging out with her rescue dog Romy. \nRegister here \n\n\n\nBSGCT PPE Talk – Going Viral: How To Tame And Train A Virus Into A Cancer-Fighting Therapy\n\n\n\n\n\n\n\n\nYour details\n\n\n\n	Title\n		\n	\n	\n	\n	\n\n\n	Name\n		*\n	\n	\n	First\n	\n\n\n	Last Name\n		*\n	\n	\n	Last\n	\n\n\n	Email\n		*\n	\n	\n	\n	\n\n\n	Organisation\n		*\n	\n	\n	\n	\n\n\n	Position / role\n		*\n	\n	\n	\n	\n\n\n	BSGCT Membership Status\n		*\n	\n						\n					 Member\n					\n					 Non-member\n\n	\n	\n\n\n\n	\n\nSubmit\n\n\n\n		\n			\n			\n			\n				If you are human\, leave this field blank.
URL:https://bsgct.org/event/bsgct-ppe-talk-going-viral-how-to-tame-and-train-a-virus-into-a-cancer-fighting-therapy/
CATEGORIES:Online Seminars,Patient and Public Engagement
ATTACH;FMTTYPE=image/png:https://bsgct.org/wp-content/uploads/2025/11/PPE_December-2025_Twitter.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20250806T183000
DTEND;TZID=UTC:20250806T193000
DTSTAMP:20250731T123124Z
CREATED:20250729T140856Z
LAST-MODIFIED:20250731T123124Z
UID:10000004-1754505000-1754508600@bsgct.org
SUMMARY:BSGCT PPE Talk - The IKEA Model: Why your cells are basically a DIY furniture manufacturer\, and how we can use that to treat genetic disease
DESCRIPTION:Virtual Only. \nREGISTRATION IS FREE – Sign up here to receive the joining link. \nBSGCT Invites you to our next Public and Patient Engagement (PPE) talk. \nJoin Dr. Carina Graham\, Research Associate\, St John’s Institute of Dermatology\, Guy’s Hospital. \nRegister here \n\n\n\nBSGCT PPE Talk – The IKEA Model: Why your cells are basically a DIY furniture manufacturer\, and how we can use that to treat genetic disease\n\n\n\n\n\n\n\n\nYour details\n\n\n\n	Title\n		\n	\n	\n	\n	\n\n\n	Name\n		*\n	\n	\n	First\n	\n\n\n	Last Name\n		*\n	\n	\n	Last\n	\n\n\n	Email\n		*\n	\n	\n	\n	\n\n\n	Organisation\n		*\n	\n	\n	\n	\n\n\n	Position / role\n		*\n	\n	\n	\n	\n\n\n	BSGCT Membership Status\n		*\n	\n						\n					 Member\n					\n					 Non-member\n\n	\n	\n\n\n\n	\n\nSubmit\n\n\n\n		\n			\n			\n			\n				If you are human\, leave this field blank.
URL:https://bsgct.org/event/bsgct-ppe-talk-dna-editing-based-therapies-for-rare-disease/
CATEGORIES:Online Seminars,Patient and Public Engagement
ATTACH;FMTTYPE=image/png:https://bsgct.org/wp-content/uploads/2025/07/BSGCT-PPE.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20250312T183000
DTEND;TZID=UTC:20250312T193000
DTSTAMP:20250312T143752Z
CREATED:20250304T102156Z
LAST-MODIFIED:20250312T143752Z
UID:10000003-1741804200-1741807800@bsgct.org
SUMMARY:Public & Patient Series - Liver directed lentiviral gene therapy for inherited cholestatic disorders
DESCRIPTION:Approximately 1 in 2500 neonates develop cholestatic jaundice\, often due to rare genetic disorders with no cure and severe morbidity. This talk will explore how innovative lentiviral gene therapies could transform treatment\, using ARC syndrome as a case study. We will highlight key breakthroughs in optimizing gene delivery and ensuring vector safety— crucial steps toward life-changing therapies. \nDr Claudiu Cozmescu is a postdoctoral researcher in the Genetics and Genomic Medicine Research Teaching Department at the UCL Institute of Child Health\, focused on advancing in vivo lentiviral gene therapy for inherited liver and multi-organ disorders. He leads cutting-edge projects\, including “Multi-organ lentiviral gene therapy for ARC Syndrome\,” funded by LifeArc\, and has secured funding from Action Medical Research and the National Institute for Health and Care Research as PI and Co-PI to develop novel treatments for related genetic conditions. With a strong background in gene therapy and genetic technologies\, Dr Cozmescu’s work bridges innovative research with real-world clinical applications. He also helps shape the next generation of scientists as Co-Lead of two MSc core modules at the UCL Institute of Child Health: “Molecular Aspects of Cell and Gene Therapy” and “Clinical Applications of Cell and Gene Therapy.” \nFREE REGISTRATION \nPlease note the joining link will be emailed to you prior to the start of this event.
URL:https://bsgct.org/event/public-patient-series-liver-directed-lentiviral-gene-therapy-for-inherited-cholestatic-disorders/
CATEGORIES:Online Seminars,Patient and Public Engagement
ATTACH;FMTTYPE=image/png:https://bsgct.org/wp-content/uploads/2025/03/BSGCT-PostcardsYT-Thumbnails.png
LOCATION:https://bsgct.org/event/public-patient-series-liver-directed-lentiviral-gene-therapy-for-inherited-cholestatic-disorders/
END:VEVENT
END:VCALENDAR